Q1 2024 Key Financial Figures – Earnings before Interest, Taxes, Depreciation and Amortization (ΕΒΙΤDA) increased by 15.9%
Peania, 23 May 2024 – Lavipharm Group’s total earnings before interest, taxes, depreciation, and amortisation (EBITDA) during the First Quarter of 2024 posted an increase of 15.9%, amounting to EUR 2.85 million, up from EUR 2.46 million during Q1 2023. The Group's EBITDA from continuing...
23 May, 2024